The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

consistent with CagriSema’s broader class of GLP-1 receptor agonist drugs. Novo declined to comment for this story as it is in the regulatory quiet period ahead of quarterly results on Wednesday.

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

GLP-1 drugs are also engineered peptides ... scalable and combinable portfolio of injectable and oral NuSH analog peptides for the treatment of obesity, overweight and related conditions ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...